Full Picture

Extension usage examples:

Here's how our browser extension sees the article:
May be slightly imbalanced

Article summary:

1. Molecular correlates of durable remission, adaptive resistance, or primary resistance were identified in older patients with AML receiving venetoclax-based combinations.

2. Determinants of anti-PD-1 response and resistance were studied in clear cell renal cell carcinoma patients.

3. ADAPTeR is a prospective phase II study of nivolumab in treatment-naive patients.

Article analysis: